title: [Leukemias induced by anticancer chemotherapies].
abstract: The frequency of leukemia and myelodysplasia following treatment with cytotoxic agents is increasing. Theses treatment-related leukemias raise both theoretical and practical concerns. On a theoretical basis, cytogenetic and molecular abnormalities described constitute useful models to study leukemogenesis. On a practical basis, prognosis of treatment related-leukemia is somehow unfavorable and implies to take in account this risk in the development of combination therapy for solid tumors or hematological malignancies. There are two distinctive types of treatment-induced leukemia: those secondary after alkylating agents and those secondary after topoisomerase-II- inhibitors. These two types of leukemia after regarding their clinical and their hematological characteristics, but also regarding their prognosis and their associated molecular abnormalities. Leukemias induced by alkylating agents occur generally 5 or 6 years after the beginning of the chemotherapy and are preceded by a more or less long phase of pancytopenia or myelodysplasia and according to their cytologic aspects are difficult to be classified within FAB classification. Their prognosis is pejorative. The most commonly found cytogenetic abnormalities associated with these types of induced leukemia are losses or deletions of chromosomes 5 and 7. Leukemias induced by topoisomerase-II-inhibitors occur shortly after the treatment (12 to 30 months), they begin generally suddenly without preleukemia prodom and their more frequent cytological aspects are M4 and M5 type. The prognosis is less severe than alkylating agent related forms with higher response rates and is dependant of discovered cytogenetic abnormalities. The more frequent molecular abnormalities are not chromosome deletions but balanced translocations. They affect particularly the MLL gene located at band 11q23. Other translocations have been described in this type of leukemia and are comparable to the one found in the de novo leukemia (t8;21, t15;17) for example. The evaluation of the risk of treatment-related leukemia for a given chemotherapeutic agent is difficult as for as current treatment use the combination of several agents potentially leukemogenic (chemotherapy and radiotherapy, combination chemotherapy). It is necessary to set up an up-dated data register in order to centralize all therapy-related myelodysplasia and leukemia within the treatment of a given type of cancer.
authors.affiliation: Service d'hématologie clinique, Hôtel-Dieu CHU, place Alexis-Ricordeau, 44093 Nantes Cedex 01.
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
mesh_terms: D000208:Acute Disease; D004791:Enzyme Inhibitors / Q000009:adverse effects; D006801:Humans; D007938:Leukemia / Q000139:chemically induced* / Q000235:genetics / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000235:genetics / Q000628:therapy; D018570:Risk Assessment; D059005:Topoisomerase II Inhibitors
chemical_list: D004791:Enzyme Inhibitors; D059005:Topoisomerase II Inhibitors
vernacular_title: Les leucémies induites par les chimiothérapies anticancéreuses.